Disruptor with a dose of care

Company

13 Aug 2024 | 5 Min Read

Mankind Pharma focuses on chronic therapies in healthcare

Expanding presence in new geographies and enhancing portfolio

Strong foothold in domestic prescription and OTC market

Financials indicate strong growth potential with a BUY rating

Significant growth in therapy and leading subgroups in anti-infectives

10% growth in GI therapy with a focus on chronic segments